Summary
The corticosterone-sensitive extraneuronal transport mechanism for noradrenaline (uptake2) removes the neurotransmitter from the extracellular space. Recently, an experimental model for uptake2 has been introduced which is based on tissue culture techniques (human Caki-1 cells). The present study describes some properties of uptake2 in Caki-1 cells and introduces a new substrate, i.e., 1-methyl-4-phenylpyridinium (MPP+).
Experiments on Caki-1 cells disclosed disadvantages of tritiated noradrenaline as substrate for the investigation of uptake2. The initial rate of 3H-noradrenaline transport [kin = 0.58 μl/(mg protein · min)] was low compared with other cellular transport systems and intracellular noradrenaline was subject to rapid metabolism (kO-methylation = 0.54 min−1). The neurotoxin MPP+ was found to be a good substrate of uptake2. Initial rates of specific 3H-MPP+ transport into Caki-1 cells were saturable, the Km being 24 μmol/l and the Vmax being 420 pmol/(mg protein · min). The rate constant of specific inward transport was 34 times higher [19.6 μmol/l (mg protein · min)] than that of 3H-noradrenaline. The ratio specific over non-specific transport was considerably higher for 3H-MPP+ (12.6) than for 3H-noradrenaline (3.0). 3H-MPP+ transport into Caki-1 cells was inhibited by various inhibitors of uptake2. The highly significant positive correlation (p < 0.001, r = 0.986, n = 7) between the IC50's for the inhibition of the transport of 3H-noradrenaline and 3H-MPP+, respectively, proves the hypothesis that MPP+ enters Caki-1 cells via uptake2. 3H-MPP+ is taken up via uptake2 not only by Caki-1 cells but also by the isolated perfused rat heart which is another established model of uptake2.
Tritiated MPP+ is a new and convenient tool for the investigation of uptake2. The rate constant for inward transport, the factor of accumulation and the ratio specific over non-specific transport are considerably higher for 3H-MPP+ than for 3H-noradrenaline. In uptake studies with 3H-MPP+ inhibition of intracellular noradrenaline-metabolizing enzymes is not necessary. In tissues and tissue cultures which possess fewer uptake2 carriers than Caki-1 cells or the rat heart, the identification and characterization of uptake2 can be expected to be greatly facilitated by the use of 3H-MPP+.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bönisch H, Trendelenburg U (1974) Extraneuronal removal, accumulation and O-methylation of isoprenaline in the perfused heart. Naunyn-Schmiedeberg's Arch Pharmacol 283:191–218
Bönisch H, Uhlig W, Trendelenburg U (1974) Analysis of the compartments involved in the extraneuronal storage and metabolism of isoprenaline in the perfused heart. Naunyn-Schmiedeberg's Arch Pharmacol 283:223–244
Cheng Y, Prusoff WH (1973) Relationship between the inhibition constants (Ki) and the concentration which causes 50% inhibition of an enzymatic reaction. Biochem Pharmacol 22:403–411
Chiba K, Trevor A, Castagnoli N (1984) Metabolism of the neurotoxic tertiary amine MPTP by brain monoamine oxidase. Biochem Biophys Res Commun 120:574–578
De la Lande IS, Marino V, Lavranos T, Kennedy JA, Parker DAS, Seamark RF (1991) Distribution of extraneuronal uptake1 in reproductive tissues: studies on cells in culture. J Neural Transm [Suppl] 34:37–42
Eisenhofer G, Smolich JJ, Esler MD (1992) Disposition of endogenous adrenaline compared to noradrenaline released by cardiac sympathetic nerves in the anaesthetized dog. Naunyn-Schmiedeberg's Arch Pharmacol 345:160–171
Fiebig ER, Trendelenburg U (1978) The neuronal and extra-neuronal uptake and metabolism of 3H-(−)-noradrenaline in the perfused rat heart. Naunyn-Schmiedeberg's Arch Pharmacol 303: 21–35
Gillespie JS (1976) Extraneuronal uptake of catecholamines in smooth muscle and connective tissue. In: Paton DM (ed) The mechanism of neuronal and extraneuronal transport of catecholamines. Raven Press, New York, pp 325–354
Graefe K-H, Stefano FJE, Langer SZ (1973) Preferential metabolism of 3H-(−)-norepinephrine through the deaminated glycol in the rat vas deferens. Biochem Pharmacol 22:1147–1160
Grohmann M, Trendelenburg U (1984) The substrate specificity of uptake2 in the rat heart. Naunyn-Schmiedeberg's Arch Pharmacol 328:164–173
Hay R, Macy M, Chen TR, MacClintoc P, Reid Y (1988) American type culture collection catalogue of cell lines and hybridomas; 6th edn. American type culture collection, Rockville, Md., USA
Iversen LL (1965) The uptake of catechol amines at high perfusion concentrations in the rat isolated heart: A novel catechol amine uptake process. Br J Pharmacol 25:18–33
Javitch JA, Snyder SH (1985) Uptake of MPP+ by dopamine neurons explains selectivity of parkinsonism-inducing neurotoxin, MPTP. Eur J Pharmacol 106:455–456
Javitch JA, D'Amato RJ, Strittmatter SM, Snyder SH (1985) Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurones explains selective toxicity. Proc Natl Acad Sci USA 82:2173–2177
Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–275
Nikodijevic B, Senoh S, Daly JW, Creveling CR (1970) Catechol-O-methyltransferase. II. A new class of inhibitors of catechol-O-methyltransferase: 3,5-dihydroxy-4-methoxybenzoic acid and related compounds. J Pharmacol Exp Ther 174:83–93
Russ H, Engel W, Sonna J (1992) Cyanine-derived dyes as a novel class of potent inhibitors of extraneuronal noradrenaline transport (uptake2). Naunyn-Schmiedeberg's Arch Pharmacol [Suppl] 345:409
Sayre LM (1989) Biochemical mechanism of action of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicol Lett 48:121–149
Schömig E, Schönfeld C-L (1990) Extraneuronal noradrenaline transport (uptake2) in a human cell line (Caki-1 cells). NaunynSchmiedeberg's Arch Pharmacol 341:404–410
Schömig E, Körber M, Bönisch H (1988) Kinetic evidence for a common binding site for substrates and inhibitors of the neuronal noradrenaline carrier. Naunyn-Schmiedeberg's Arch Pharmacol 337:626–632
Schömig E, Babin-Ebell J, Russ H, Trendelenburg U (1992) The force driving the extraneuronal transport mechanism for catecholamines (uptake2). Naunyn-Schmiedeberg's Arch Pharmacol 345:437–443
Schwegler JS, Schömig E, Heuner A, Silbernagl S (1990) Development of high-capacity, low-affinity L-arginine transport in a proximal tubular cell line during differentiation. In: Lubec G, Rosenthal GA (eds) Amino acids: chemistry, biology and medicine. ESCOM, Rotterdam, pp 1017–1028
Segel IH (1975) Enzyme kinetics: behavior and analysis of rapid equilibrium and steady state enzyme systems. John Wiley, New York London Sydney Toronto
Trendelenburg U (1988) The extraneuronal uptake and metabolism of catecholamines. In: Trendelenburg U, Weiner N (eds) Catecholamines I (Handb Exp Pharmacol, vol 90). Springer, Berlin Heidelberg New York London Tokyo, pp 279–319
Van den Bosch L, De Smedt H, Borghgraef R (1989) Characteristics of Na+-dependent hexose transport in OK, an established renal epithelial cell line. Biochem Biophys Acta 979:91–98
Wilkinson L (1989) SYSTAT: the system for statistics, SYSTAT Inc., Evanston, Ill., USA
Author information
Authors and Affiliations
Additional information
Supported by the Deutsche Forschungsgemeinschaft (SFB 176)
Send offprint requests to H. Russ at the above address
Rights and permissions
About this article
Cite this article
Russ, H., Gliese, M., Sonna, J. et al. The extraneuronal transport mechanism for noradrenaline (uptake2) avidly transports 1-methyl-4-phenylpyridinium (MPP+). Naunyn-Schmiedeberg's Arch Pharmacol 346, 158–165 (1992). https://doi.org/10.1007/BF00165297
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00165297